1004305-27-4

Basic information

• Product Name: 2,6-dimethoxy-4-pentylbenzeneboronic acid
• Synonyms: 2,6-dimethoxy-4-pentylbenzeneboronic acid
• CAS NO: 1004305-27-4
• Molecular Weight: 252.118
• Mol File: 1004305-27-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2,6-dimethoxy-4-pentylbenzeneboronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-dimethoxy-4-pentylbenzeneboronic acid(1004305-27-4)
• EPA Substance Registry System: 2,6-dimethoxy-4-pentylbenzeneboronic acid(1004305-27-4)

Safety Data

• Hazardous Substances Data: 1004305-27-4(Hazardous Substances Data)

Usage

Structure

Benzene ring with two methoxy groups at the 2 and 6 positions, and a pentyl group at the 4 position

Type of compound

Boronic acid derivative

Usage

Building block in organic synthesis for creating pharmaceuticals, agrochemicals, and materials

Reactivity

Participates in Suzuki-Miyaura cross-coupling reactions, useful for constructing complex organic molecules

Importance

Valuable tool in organic chemistry research and development due to its unique structure and reactivity.

Upstream product

• 121-43-7 Trimethyl borate 
• 22976-40-5 1,3-dimethoxy-5-pentylbenzene 

Relevant articles and documents

D3h-symmetrical hydrogen-bonding unit as a saccharide recognition and self-assembling module

(Chemical Equation Presented) A D3h-symmetrical triresorcinol module 1,3,5-tris(2,6-dihydroxy-4-pentylphenyl)benzene (3) was investigated in terms of its hydrogen-bonding ability for glycoside recognition and self-association. When 3 was treate

Method for preparing aromatic boronic acid

The invention discloses a method for preparing aromatic ring boric acid, which comprises the following steps of: (1) firstly, leading the mixed solution of aromatic ring compounds, n-butyllithium and a chelant with nitrogen heterocycle to have a reaction

FATTY ACID AMIDE HYDROLASE INHIBITORS

Disclosed are compounds of formula R-X-Y that may be used to inhibit the action of fatty acid amide hydrolase (FAAH). Inhibition of fatty acid amide hydrolase (FAAH) will slow the normal degradation and inactivation of endogenous cannabinoid ligands by FAAH hydrolysis and allow higher levels of those endogenous cannabinergic ligands to remain present. These higher levels of endocannabinoid ligands provide increased stimulation of the cannabinoid CBl and CB2 receptors and produce physiological effects related to the activation of the cannabinoid receptors. They will also enhance the effects of other exogenous cannabinergic ligands and allow them to produce their effects at lower concentrations as compared to systems in which fatty acid amide hydrolase (FAAH) action is hot inhibited. Thus, a compound that inhibits the inactivation of endogenous cannabinoid ligands by fatty acid amide hydrolase (FAAH) may increase the levels of endocannabinoids and, thus, enhance the activation of cannabinoid receptors. Thus, the compound may not directly modulate the cannabinoid receptors but has the effect of indirectly stimulating the cannabinoid receptors by increasing the levels of endocannabinoid ligands. It may also enhance the effects and duration of action of other exogenous cannabinergic ligands that are administered in order to elicit a cannabinergic response.